

Friday, May 30, 2003

COMPANY PRESS RELEASE

Transgenomic Introduces High Sensitivity Mutation Scanning Technology to Clinical Oncology Researchers at American Society of Clinical Oncology (ASCO) Annual Meeting

Chicago, Ill., May 30 / PRNewswire / -- Transgenomic Inc. (Nasdaq: [TBIO](#)) announced today plans to introduce its WAVE[®] HS High Sensitivity System at the ASCO annual meeting being held May 31-June 2. The technology embodied in this system offers an enhanced ability to detect low-abundance mutations. This is an important capability for the detection of somatic mutations associated with cancer, an area of significant and increasing interest for investigators in clinical oncology.

A number of important genes associated with cancer are complex, spanning large chromosomal regions and characterized by a diverse set of mutations that have been observed in patients. "Since its launch in 1997, our WAVE[®] System has provided an accurate and cost-effective solution when the ability to scan for all possible mutations is critical," said Collin D'Silva, Transgenomic's CEO. "In addition, the WAVE System has proven highly effective in detecting low-abundance genetic variations, which is particularly valuable for the detection of new somatic mutations during the course of cancer progression or mutations associated with the emergence of drug resistance. With the introduction of our new high-sensitivity detection technology, we are now able to offer analytical sensitivity that is enhanced by orders of magnitude, taking an already powerful tool and improving upon it." D'Silva added, "This technology has already been validated by customers in the field of cancer research and is gaining market acceptance. We believe this innovation has significant implications for cancer research and diagnostics, particularly in light of increasing emphasis on the concept of targeted therapeutic intervention in oncology."

This technology will also be highlighted at the upcoming 94th annual meeting of the American Association for Cancer Research (AACR), to be held July 11-14 in Washington, DC. Transgenomic scientists will make two presentations describing results obtained with the company's newest technology. Transgenomic customers will give more than 20 additional presentations spanning a variety of cancer research topics. These topics will include cancer biomarkers and risk factors, molecular markers of prognosis, pharmacogenetics and mechanisms of drug resistance.

About Transgenomic

Transgenomic provides versatile and innovative research tools and related consumable products to the life sciences industry for the synthesis, separation, analysis and purification of nucleic acids and a wide variety of nucleic acid-based specialty chemicals. Transgenomic's biosystems segment offers its WAVE Systems and associated consumables. These systems are specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification. These systems have broad applicability to genetic research and molecular diagnostics. To date there have been approximately one thousand systems installed in over 30 countries around the world.

Through its nucleic acids business segment, Transgenomic provides specialty chemicals, including advanced nucleic acid building blocks and associated reagents, used in applications such as genetic diagnostics and therapeutics. Manufacturing operations include a cGMP facility for the synthesis of oligonucleotides.

For more information about the innovative genomics research tools developed and marketed by Transgenomic, please visit the company's Web site at www.transgenomic.com.

Forward Looking Statement

Certain statements in this press release constitute "forward-looking statements" of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to the applicability of the Company's

technology to cancer research and diagnostics and its ability to gain market acceptance. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's reports to the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release, and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

#

For more information, please contact:

Mitchell L. Murphy
Transgenomic Inc.
402-452-5418
mmurphy@transgenomic.com

Robert J. Pogulis, Ph.D.
Transgenomic Inc.
845-782-9617
rpogulis@transgenomic.com